Pfizer forecasts $26bn from annual sales of Covid-19 vaccine
by Julia Kollewe from on (#5HDQF)
Vaccine will generate 73% more than forecast based on contracts signed until mid-April
The US drugmaker Pfizer has smashed its sales forecasts and now expects to bring in $26bn (19bn) of revenue from its Covid-19 vaccine this year, with its soaraway product accounting for more than a third of the company's annual income.
The company had expected the vaccine to bring in $15bn over the course of 2021, and the 73% increase in expected revenues to $26bn is still likely to be an underestimate as it counts only orders received by the middle of April and Pfizer is expected to sign more multibillion dollar supply contracts.
Continue reading...